Copper Oxodotreotide

CHEMBL4302413 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A copper-labeled form of a somatostatin analog used to target tumors that express somatostatin receptors, such as certain prostate cancers. It delivers therapeutic or diagnostic payloads directly to cancer cells.

Aires thérapeutiques

Oncology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A copper-labeled form of a somatostatin analog used to target tumors that express somatostatin receptors, such as certain prostate cancers. It delivers therapeutic or diagnostic payloads directly to cancer cells.

Yes, Copper Oxodotreotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4302413. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Copper Oxodotreotide sur PillFYI

Données Clés

Liens externes

ChEMBL CHEMBL4302413

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.